Insmed Inc
F:IM8N
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Insmed Inc
F:IM8N
|
US |
|
F
|
FutureFuel Corp
F:3FF
|
US |
Intrinsic Value
The intrinsic value of 
Insmed Inc (IM8N) under the Base Case is 95.47 EUR per share.
Compared with the current market price of 85.07 EUR, the stock appears
Undervalued by 11% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Insmed Does
Insmed is a biopharmaceutical company that develops and sells medicines for serious, chronic diseases with few good treatment options, especially rare lung and inflammatory disorders. Its lead products are inhaled and oral therapies used by patients with conditions such as non-tuberculous mycobacterial lung disease and bronchiectasis, where infection and airway damage make breathing harder and daily care more complex.
- Headquarters
- United States of America US
- Employees
- 1 664
- IPO date
- Feb 15, 1991
Insmed has a narrow economic moat
Patents and legal protection against competing copies prevent rivals from freely copying Insmed’s medicines and undercutting their prices. These protections give Insmed room to earn returns from treatments developed for serious lung diseases.
Read the full moat analysis
Revenue & Expenses Breakdown
Insmed Inc
Earnings Waterfall
Insmed Inc
The intrinsic value for Insmed Inc (IM8N) under the Base Case is 95.47 EUR.
Compared with the current market price of 85.07 EUR, the stock appears Undervalued by 11% .